Brian Robb Douglass - 31 Dec 2025 Form 4 Insider Report for REPLIGEN CORP (RGEN)

Reporting relationship: CHIEF PRODUCT OFFICER
Issuer ticker: RGEN
Reported as of: 31 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jan 2026, 16:32:03 UTC
Next SEC filing: 03 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Meghan Stapleton (Attorney in Fact)

Key filing fact

Brian Robb Douglass filed Form 4 for REPLIGEN CORP (RGEN) on 12 Jan 2026.

Key facts

This page summarizes Brian Robb Douglass's Form 4 filing for REPLIGEN CORP (RGEN).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Jan 2026, 16:32.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002104618 Primary reporting owner

Douglass Brian Robb

Relationship: CHIEF PRODUCT OFFICER
Address: C/O REPLIGEN CORPORATION, 41 SEYON ST., BLDG 1, STE 100, WALTHAM
Signature: /s/ Meghan Stapleton (Attorney in Fact)
Signature date: 12 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RGEN transaction

Common Stock

Award

Transaction value: $0
Shares: +2,288
Change %: +37%
Price: $0.000000
Shares after: 8,540
Date: 31 Dec 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RGEN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +2,143
Change %
Price: $0.000000
Shares after: 2,143
Date: 31 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,143
Exercise price: $163.86
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Mr. Douglass was awarded 2,288 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in substantially equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock.

Footnote F2

The shares will vest in substantially equal installments over a three-year period with each such vesting date occurring on the anniversary of the grant date.